BioNTech reported a disappointing quarter, moving from a €259.5 million profit a year ago to a net loss of €305 million. The company posted a per-share loss of €1.25 on revenue of €907.4 million, which was much worse than analysts’ forecasts of a €0.45 loss on €768.3 million in revenue.
The company’s outlook added to the disappointment. Management expects full-year 2026 revenue between €2 billion and €2.3 billion, which is well below the roughly €2.75 billion analysts had predicted. This gap suggests there are ongoing challenges, not just a one-time setback.
Shares dropped about 17% in premarket trading, putting the stock on track for its biggest one-day decline in over four years.
The worsening financial situation comes as the company faces a major leadership change. The co-founders, who are also the chief executive and chief medical officer and started BioNTech in 2008, announced they will leave by the end of the year to start a new biotech company. The supervisory board has begun looking for their replacements. BioNTech plans to give some rights and mRNA technologies to the new company in return for a minority stake, milestone payments, and royalties.
The leadership changes make an already tough situation even harder. Revenue from BioNTech’s main product, developed in partnership, has been declining since the peak of the pandemic. Management expects this decline to continue in both Europe and the U.S. through 2026. Meanwhile, a separate cancer partnership is expected to bring in about the same revenue as last year. In the United States, where mRNA technology — the foundation of BioNTech’s vaccine and cancer immunotherapy pipeline — has come under heightened scrutiny following a change in federal health leadership. The current administration has adopted a skeptical posture toward mRNA-based therapeutics, creating uncertainty around the regulatory pathway for next-generation products.
Prior to Tuesday’s selloff, BioNTech’s U.S.-listed shares had only made small gains in 2026, falling far behind the strong recoveries seen at other vaccine makers.
Featured CoursesRecent news
ServiceNow and Software Stocks Lead Sector Recovery on AI Hopes
Software stocks are making a comeback. ServiceNow jumped 8.8% on Monday, marking its largest one-day gain in over a year. This surge followed BofA Securities reinstating coverage with a Buy rating, which helped restore investor confidence in a sector that faced pressure in 2026 over concerns that AI might replace, not support, enterprise software. Here’s […]
GE Aerospace Stock Rises as AI Cuts Hypersonic Engine Design Time
GE Aerospace is showing investors what artificial intelligence looks like when applied to one of the world’s most technically demanding industries. Shares rose 1.58% Tuesday as the company revealed that researchers at its Niskayuna, New York, facility used an in-house generative AI tool to produce a preliminary hypersonic ramjet engine design, compressing a process that […]
Nvidia Shares Slip 1.1%: Why a 3-Day Losing Streak Could Be Good News
Nvidia is heading into its most anticipated earnings report of the year on the back foot, and that may be exactly what the stock needs. Shares fell 1.1% in premarket trading Tuesday, extending a three-day pullback from last Thursday’s closing high of $235.74. For investors watching closely, a lower entry point ahead of Wednesday’s results […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.